- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00634816
Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers
Cross-sectional Study of Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers
Study Overview
Status
Intervention / Treatment
Detailed Description
Specific subgroups of children who survive treatment for childhood malignancies have been shown to develop relative osteopenia following chemotherapy and are felt to be at risk for developing osteoporosis later in life due to their inability to reach peak bone mass during childhood. However, currently, there is no conclusive evidence that survivors of pediatric solid malignancies are at risk for these problems due to small numbers of patients analyzed. Our SUNY Upstate Medical University Pediatric Oncology Long-term Follow-up Clinic has recently established a coalition of other upstate New York cancer centers which allows access to a large number of these patients. The purpose is to perform a cross-sectional study of bone mineral density using dual-energy X-ray absorptiometry (DEXA) in adult survivors of solid pediatric tumors. The primary hypothesis is that pediatric solid cancer survivors will demonstrate significantly lower bone mineral density (BMD) compared to established age group controls. Identification of these patients as high risk for development of osteoporosis will allow clinical trials using novel and established agents.
This study has been ongoing for 5 years. To date there have been no problems with the conduct of this study. A total of 38 subjects that have been enrolled. Analysis of research to date reveals that solid tumor survivors are at increased risk for early osteopenia/osteoporosis. No subjects have withdrawn or been excluded for any reason other than inclusion/exclusion criteria since inception of the study. The study will be ongoing for recruitment of subjects and analysis.
There was one amendment made to the protocol. The amendment was to increase the upper age of the subjects to 40 years. This amendment was made due to that although our multivariate analysis showed a relationship with number of chemotherapy drugs, our statistical power to examine according to multiple other variables, such as individual diagnosis, was limited by the relatively small numbers of patients.
An article was submitted to the Journal of Pediatric Hematology Oncology and printed in the May 2005 issue.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
Syracuse, New York, United States, 13202
- SUNY Upstate Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients from the SUNY Upstate Medical Center Pediatric Oncology Long-term Survivor Clinic who were treated for solid tumors and lymphomas with chemotherapy beginning at age less than 16 will be recruited for participation. Patients must be less than 40 years of age to participate.
Exclusion Criteria:
- Patients treated for Acute Lymphocytic Leukemia (ALL) and those who received cranial irradiation or total body irradiation (groups already known to be at high risk for osteoporosis) will be excluded. In addition, any patient who received non-autologous bone marrow transplant will be excluded, as these patients may have graft versus host disease (also known to be associated with osteopenia).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chemotherapy recipients
Subjects who have undergone chemotherapy will receive DXA scan
|
The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion.
Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Osteoporosis after chemotherapy
Time Frame: April 2003-April 2006
|
Does chemotherapy increase the risk of osteoporosis in patients
|
April 2003-April 2006
|
Collaborators and Investigators
Investigators
- Principal Investigator: Timothy A Damron, MD, State University of New York - Upstate Medical University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cross sectional
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Regional Osteoporosis as a Result of Chemotherapy
-
West Virginia UniversityCompletedInjury as a Result of PositioningUnited States
-
Massachusetts General HospitalWithdrawnAnaphylaxis as a Result of Allergen or Venom ImmunotherapyUnited States
-
MindRhythm, Inc.Not yet recruitingHealthy | Cranial Waveform in Normal Patients as a Result of Cardiac CycleUnited States
-
Laval UniversityUnknownUnderstanding of Community Immunity as a Concept
-
Memorial Sloan Kettering Cancer CenterAckerman Institute for FamilyActive, not recruitingSupport of the Family as a Caregiving SystemUnited States
-
Paradigm SpineCompletedIntermittent Neurogenic Claudication (INC) as a Result of Spinal StenosisNetherlands
-
Home Skinovations Ltd.CompletedClinical and Usability Study to Determine Safety and Efficacy of the Clear Device for Acne TreatmentMonitor Acne Lessions Count Reduction as Result of Usinfg the DeviceCanada
-
Indonesia UniversityCompletedQnox Values as a Predictor of Pain ResponseIndonesia
-
Bnai Zion Medical CenterRecruitingAssessing the Effectiveness of BFA as a Non-pharmacologic Pain Management Intervention: A Randomised Sham Controlled StudyIsrael
-
Assiut UniversityNot yet recruitingPossibility of Using microRNA30a as a Prognostic Marker in Philadelphia Positive Leukemic Patients by Measure Level of microRNA30a in Blood Sample
Clinical Trials on DXA Scan
-
University Hospital, Clermont-FerrandUnknown
-
Assiut UniversityNot yet recruiting
-
Baxalta now part of ShireTerminatedHemophilia A | Hemophilia B | Bone Mineral DensityUnited States
-
Central Hospital, Nancy, FranceUnknown
-
Herlev HospitalDanish Cancer SocietyCompletedDepression | Melanoma | Quality of Life | Pain | Cicatrix | Lymphedema | AnxietyDenmark
-
Odense University HospitalUniversity of Southern Denmark; University Hospital Schleswig-HolsteinCompleted
-
Sheffield Teaching Hospitals NHS Foundation TrustMedical Research Council; Hologic, Inc.Completed
-
University College, LondonWithdrawnPost-menopausal OsteoporosisUnited Kingdom
-
University of IowaRecruitingAsthma | Bone Density, Low | Oral Steroid-Dependent Asthma (Disorder)United States
-
CHU de Quebec-Universite LavalCompletedDiabetes Mellitus, Type 1 | Bone Health | Bone FractureCanada